Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

Urology

Volumn 68, Issue 6, 2006, Pages 1263-1267

  Morgentaler, Abraham ^a   Rhoden, Ernani Luis ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Federal School of Medical Sciences of Porto Alegre   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; FOLLOW-UP STUDIES; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845329200     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1058     Document Type: Article

References (16)

1. Morgentaler A., Bruning C.O., and DeWolf W.C. Occult prostate cancer in men with low serum testosterone levels. JAMA 276 (1996) 1904-1906
2. Zhang P.L., Bubley G., Upton M., et al. Pathological features of occult prostatic carcinoma in hypogonadal men. Prostate J 2 (2000) 74-78
3. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
4. Schatzl G., Madersbacherm S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
5. Vermeulen A., Verdonck L., and Kaufman J.M. A critical evaluation of simple methods for the estimation of FT in serum. J Clin Endocrinol Metab 84 (1999) 3666-3672
6. Mohr B.A., Guay A.T., O'Donnell A.B., et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol 62 (2005) 64-73
7. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a PSA level ≤4 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
8. Ribeiro M., Ruff P., and Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20 (1997) 605-608
9. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment TT level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
10. Isom-Batz G., Bianco F.J., Kattan M.E., et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173 (2005) 1935-1937
11. Chodak G.W., Vogelzang N.J., Caplan R.J., et al., Zoladex Study Group. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265 (1991) 618-621
12. Raivio T., Santti H., Schatzl G., et al. Reduced circulating androgen bioreactivity in patients with prostate cancer. Prostate 55 (2003) 194-198
13. Schatzl G., Madersbacher S., Haitel A., et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 169 (2003) 1312-1315
14. Miller L.R., Partin A.W., Chan D.W., et al. Influence of radical prostatectomy on serum hormone levels. J Urol 160 (1998) 449-453
15. Zhang P.L., Rosen S., Veeramachaneni R., et al. Association between prostate cancer and serum testosterone levels. Prostate 53 (2002) 179-182
16. Schaeffer E.M., and Walsh P.C. Re: risks of testosterone replacement. N Engl J Med 350 (2004) 2004-2006